Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eftozanermin alfa + venetoclax
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**eftozanermin alfa + venetoclax** is a combination therapy of eftozanermin alfa (formerly ABBV-621, a TRAIL receptor agonist) and venetoclax (a BCL-2 inhibitor). Eftozanermin alfa is a recombinant fusion protein that selectively binds and activates death receptors DR4 and DR5 to engage the extrinsic apoptosis pathway. Venetoclax is an orally available small molecule that inhibits the anti-apoptotic BCL-2 protein, restoring apoptosis in malignant cells via the intrinsic pathway. Together, the combination simultaneously activates extrinsic and intrinsic apoptotic pathways, which may enhance anti-leukemic efficacy. The combination has been investigated primarily in relapsed/refractory acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL)[5][1][7].
- Other names
- eftozaABBV-621 + venetoclax
02
Targets
BCL-2 (BCL-2 family)TNFRSF10A (Death receptor 4)TNFRSF10B (DR5)
Beyond the preview
Go deeper on eftozanermin alfa + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eftozanermin alfa + venetoclax.